Benedict J Chambers
Overview
Explore the profile of Benedict J Chambers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
900
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lourda M, Dzidic M, Hertwig L, Bergsten H, Palma Medina L, Sinha I, et al.
Proc Natl Acad Sci U S A
. 2021 Sep;
118(40).
PMID: 34548411
Since the outset of the COVID-19 pandemic, increasing evidence suggests that the innate immune responses play an important role in the disease development. A dysregulated inflammatory state has been proposed...
12.
Lis N, Hein Z, Ghanwat S, Ramnarayan V, Chambers B, Springer S
J Cell Sci
. 2021 Jun;
134(11).
PMID: 34085696
NKG2D (also known as KLRK1) is a crucial natural killer (NK) cell-activating receptor, and the murine cytomegalovirus (MCMV) employs multiple immunoevasins to avoid NKG2D-mediated activation. One of the MCMV immunoevasins,...
13.
Bhandage A, Friedrich L, Kanatani S, Jakobsson-Bjorken S, Escrig-Larena J, Wagner A, et al.
J Leukoc Biol
. 2021 May;
110(4):617-628.
PMID: 34028876
Protective cytotoxic and proinflammatory cytokine responses by NK cells impact the outcome of infections by Toxoplasma gondii, a common parasite in humans and other vertebrates. However, T. gondii can also...
14.
Eisinger S, Sarhan D, Boura V, Ibarlucea-Benitez I, Tyystjarvi S, Oliynyk G, et al.
Proc Natl Acad Sci U S A
. 2020 Nov;
117(50):32005-32016.
PMID: 33229588
Tumor-associated macrophages (TAMs) can have protumor properties, including suppressing immune responses, promoting vascularization and, consequently, augmenting tumor progression. To stop TAM-mediated immunosuppression, we use a novel treatment by injecting antibodies...
15.
Luu T, Wagner A, Schmied L, Meinke S, Freund J, Kambayashi T, et al.
Eur J Immunol
. 2019 Dec;
50(4):494-504.
PMID: 31834938
NK cells are innate immune cells characterized by their ability to spontaneously lyse tumor and virally infected cells. We have recently demonstrated that IL-15-sufficient DC regulate NK cell effector functions...
16.
Batyrova B, Luwaert F, Maravelia P, Miyabayashi Y, Vashist N, Stark J, et al.
Immun Inflamm Dis
. 2019 Nov;
8(1):8-23.
PMID: 31742928
Introduction: Innate lymphoid cells (ILCs) can provide early cytokine help against a variety of pathogens in the lungs and gastrointestinal tract. Type 2 ILC (ILC2) are comparable to T helper...
17.
Trittel S, Chambers B, Heise U, Guzman C, Riese P
Sci Rep
. 2019 Nov;
9(1):16362.
PMID: 31704965
The contribution of natural killer (NK) cells to the clearance of hepatic viral infections is well recognized. The recently discovered heterogeneity of NK cell populations renders them interesting targets for...
18.
Trittel S, Vashist N, Ebensen T, Chambers B, Guzman C, Riese P
Front Immunol
. 2019 Aug;
10:1849.
PMID: 31440243
Non-NK group 1 innate lymphoid cells (ILC1s), mainly investigated in the mucosal areas of the intestine, are well-known to contribute to anti-parasitic and anti-bacterial immune responses. Recently, our group revealed...
19.
Witt K, Ligtenberg M, Conti L, Lanzardo S, Ruiu R, Wallmann T, et al.
Cancer Immunol Res
. 2018 Aug;
6(11):1417-1425.
PMID: 30143536
Metastatic breast cancer is a fatal disease that responds poorly to treatment. Cancer vaccines targeting antigens expressed by metastatic breast cancer cells and cancer stem cells could function as anticancer...
20.
Vashist N, Trittel S, Ebensen T, Chambers B, Guzman C, Riese P
Front Immunol
. 2018 Apr;
9:505.
PMID: 29623077
Innate lymphoid cells (ILCs) represent diversified subsets of effector cells as well as immune regulators of mucosal immunity and are classified into group 1 ILCs, group 2 ILCs, and group...